| Mihra Taljanovic, MD | |
|
1501 N Campbell Ave, Tucson, AZ 85724-0001 | |
| (520) 694-4034 | |
| (520) 694-0216 |
| Full Name | Mihra Taljanovic |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 44 Years |
| Location | 1501 N Campbell Ave, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063584050 | NPI | - | NPPES |
| 465452 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD2021-0039 (New Mexico) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 27393 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of New Mexico Hospital | Albuquerque, NM | Hospital |
| Unm Sandoval Regional Medical Center | Rio rancho, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner -- University Medical Group | 7719899871 | 819 |
| University Of New Mexico Medical Group | 4981795267 | 1002 |
News Archive
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.
› Verified 4 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.
› Verified 4 days ago
| Entity Name | Banner - University Hospital Based Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750751566 PECOS PAC ID: 1052614294 Enrollment ID: O20160122000508 |
News Archive
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.
› Verified 4 days ago
| Entity Name | Smi Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972004489 PECOS PAC ID: 3476696220 Enrollment ID: O20180829003142 |
News Archive
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mihra Taljanovic, MD 575 E River Rd, Tucson, AZ 85704-5822 Ph: (520) 874-7400 | Mihra Taljanovic, MD 1501 N Campbell Ave, Tucson, AZ 85724-0001 Ph: (520) 694-4034 |
News Archive
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.
› Verified 4 days ago
Gary A Podolny, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 13305 E Saddlerock Rd, Tucson, AZ 85749 Phone: 520-749-3468 | |
William G Berger, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 677 N Wilmot Rd, Tucson, AZ 85711 Phone: 520-571-9599 | |
Edward E Rogoff, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2625 N Craycroft Rd, Ste 100, Tucson, AZ 85712 Phone: 520-324-4214 Fax: 520-324-2680 | |
Dr. Jose Bernardo Rebeil-de La Rosa, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2492 E River Rd, Tucson, AZ 85718 Phone: 520-722-8994 Fax: 520-624-0117 | |
Marilyn Kay Croghan, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 2625 N Craycroft Rd, Ste 100, Tucson, AZ 85712 Phone: 520-324-4214 Fax: 520-324-2680 | |
Baldassarre Stea, MD, PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: 520-694-7236 Fax: 520-626-2032 | |
Stephanie A Reddick, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5911 N Camino Preciado, Tucson, AZ 85718 Phone: 303-933-8270 Fax: 214-712-2002 |